Cover Image

AKTing on XPO1 inhibition in AML

Show other versions (1)

Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, pur...

Full description

Saved in:
Bibliographic Details
Main Authors: Göllner, Stefanie (Author) , Müller-Tidow, Carsten (Author)
Format: Article (Journal)
Language:English
Published: 26 July 2022
In: Nature cancer
Year: 2022, Volume: 3, Issue: 7, Pages: 787-789
ISSN:2662-1347
DOI:10.1038/s43018-022-00395-w
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s43018-022-00395-w
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s43018-022-00395-w
Get full text
Author Notes:Stefanie Göllner and Carsten Müller-Tidow
Description
Summary:Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor-mediated AKT activation potentiates its anti-leukemic activity.
Item Description:Gesehen am 19.08.2022
Physical Description:Online Resource
ISSN:2662-1347
DOI:10.1038/s43018-022-00395-w

Similar Items